• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice New Year’s Special | Paul LaViolette

MassDevice New Year’s Special | Paul LaViolette

December 27, 2010 By MassDevice staff

Paul LaViolette

Paul LaViolette
Partner, SV Life Sciences

Paul LaViolette, a partner at venture capital firm SV Life Sciences, has more than 28 years of global medical technology marketing and general management experience. A former COO at Boston Scientific Corp. (NYSE:BSX), LaViolette spent 15 years at the Natick devices giant, with stops as president of the cardiology and international groups. His resume also includes stints at C.R. Bard (NYSE:BCR) and the Kendall division of the erstwhile Tyco Corp. He served on the boards of Urologix (NSDQ:ULGX), Percutaneous Valve Technologies and AdvaMed and currently serves on the boards of Cameron Health, CardioFocus, Conceptus (NSDQ:CPTS), DC Devices, Direct Flow Medical, DJO Global, Thoratec Corp. (NSDQ:THOR), Trans 1 ValenTx and the Medical Device Manufacturers Assn.

We asked LaViolette for a single-word description of the investment climate for medical devices. Although his emailed response was, "Depressed," his summation of the climate going forward is decidedly sunnier:

"Within a larger environment that is exerting unprecedented pressure on the medical device development infrastructure, and related investment appetite, there remains substantial opportunity for upside if we target properly. The hurdles are greater, and thus the returns potential has to rise accordingly."

Here’s the full text of his reply, edited for grammar and clarity:

Depressed. The metrics of medtech investing clearly support this categorization. We’ve seen dramatic reductions, starting in 2008 but carrying forward through 2010, all facets of the investment chain, including: IPO, exits, exit values, venture investing and public and private company valuations. There is little debate that the financial measures of investment are down, often materially, from past experiences.

MassDevice New Year’s Special P/review

  • P/review: Introduction
  • P/review: Paul LaViolette
  • P/review: Stephen Ubl
  • P/review: David Lucchino
  • P/review: Euan Thomson
  • P/review: Brian DeChristopher
  • P/review: Christopher Delporte
  • P/review: Don Hardison
  • P/review: Brent Hudson

  • P/review: Hamid Tatabaie
  • P/review: Patrick Dentinger
  • P/review: Nancy Briefs
  • P/review: Brian Concannon
  • P/review: Ryan Howard
  • P/review: Ed Berger
  • P/review: Top stories of 2010

I believe “depressed” is also an appropriate characterization of the psychology of the market, and of the investment outlook for the near term. Investors are concerned about underlying fundamentals in health care market returns as they see the compounding factors of health care delivery reform and regulatory reform creating uncertainty and sustained downward pressure on market health.

HC reform theoretically adds demanding patients to the system, but it is widely held that most patients who really needed care — particularly involving procedure-based medical devices — received it through one form or another of uncompensated care. As such, the industry is generally not anticipating a spike in demand but is viewing that the aggregate economic pressures of reform, government involvement in programs, emphasis on cost effectiveness, reduced hospital operating margins, reduced physician economics, etc., will combine to create inevitable downward pressure on the economics of the device sector.

Lastly, there is a widely held industry belief that FDA, through its science and reform initiatives, is both “raising the bar” on approval requirements while also pulling back from industry interaction. This combination of lost transparency and protracted approvals extends the pre-market status of technologies, which in turn creates higher operating costs for large companies or protracted holding periods for venture portfolios, and each of these further dilutes investor returns in the device sector. So, while the broader economy may “bounce back” from its significant financial sector and unemployment set-backs, the medical device investment category faces an alignment of forces that make a bounce back from the abrupt financial market meltdown highly improbable.

Reguatory and payment reforms weigh heavily in investor calculus, and are unlikely to settle with either sufficient speed or clarity to be helpful to investor mindsets in 2011. FDA’s 510(k) reform initiative is a great example. The industry depends upon the Agency to approve 15 new 510(k)s each day, and the 510(k) process is applied to well over 90% of all device approvals. Any significant alteration to such a vastly relied on system will send powerful reverberations through the industry. When considering the number and scope of changes being contemplated, it’s easy to understand why the investment community is frozen in anticipation of what the next, improved system will require and how it will be implemented. We also have operated on the presumption that review times and evidence burdens should be proportionate to device risk, and that new scientific evidence should not be required for devices that neither create substantial risk nor make new indications claims. These assumptions are currently being challenged, and there are very clear signs that the core basis upon which lower-risk devices have historically been approved may be overturned, despite data showing that the overwhelming majority (99%+) of all approved 510(k) devices in the past decade have never been involved in a Class I recall. We know that 510(k) approval times have doubled from 1999-2009. That said, overall timelines remain reasonably short and the process is today quite navigable for most. The changes being contemplated to this system are, in the view of most industry experts, severely threaten the functionality of the system that today produces the majority of all new devices for use in the health care system.

Despite these macro systemic and economic factors, I am optimistic that new technologies will be an important source of vitality for the health care system and a vital component of our future requirement to treat more patients to a higher level of care while consuming fewer resources. We are clearly worsening our own system burdens with diseases derived from obesity, including diabetes, hypertension, osteoarthritis and vascular disease. New treatments in these areas are going to provide important solutions. We are faced with a demographic boon for aged patients having general health but losing quality of life, for whom prosthetic devices in vision, hearing and ambulation will play a major role. We still invest inordinate amounts in chronic diseases in the form of low-value maintenance costs (best examples: Chronic Heart Failure, chronic wound management and limb ischemia from diabetes). These dollars can be “converted” to a higher value purpose by intervening with medical technology to actually change the course of the disease rather than palliating symptoms. This approach to medical markets can create major new device market opportunities while adding zero expense dollars to the health care system.

I hope to convey that, within a larger environment that is exerting unprecedented pressure on the medical device development infrastructure, and related investment appetite, there remains substantial opportunity for upside if we target properly. The hurdles are greater, and thus the returns potential has to rise accordingly.

Filed Under: Business/Financial News Tagged With: SV Life Sciences, Venture Capital/Private Equity

In case you missed it

  • The road to a robot: Medtronic’s development process for Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • GE Healthcare to invest $50M in Pulsenmore to enter homecare segment

RSS From Medical Design & Outsourcing

  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS